Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsSecurities - TradableShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Common Equity: 2022-2024

Historic Common Equity for Praxis Precision Medicines (PRAX) over the last 3 years, with Dec 2024 value amounting to $445.4 million.

  • Praxis Precision Medicines' Common Equity fell 10.23% to $343.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $343.5 million, marking a year-over-year decrease of 10.23%. This contributed to the annual value of $445.4 million for FY2024, which is 539.38% up from last year.
  • According to the latest figures from FY2024, Praxis Precision Medicines' Common Equity is $445.4 million, which was up 539.38% from $69.7 million recorded in FY2023.
  • In the past 5 years, Praxis Precision Medicines' Common Equity registered a high of $445.4 million during FY2024, and its lowest value of $69.7 million during FY2023.
  • For the 3-year period, Praxis Precision Medicines' Common Equity averaged around $197.1 million, with its median value being $76.1 million (2022).
  • In the last 5 years, Praxis Precision Medicines' Common Equity declined by 8.46% in 2023 and then surged by 539.38% in 2024.
  • Over the past 3 years, Praxis Precision Medicines' Common Equity (Yearly) stood at $76.1 million in 2022, then fell by 8.46% to $69.7 million in 2023, then spiked by 539.38% to $445.4 million in 2024.